RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT techreview: RT A_Aspuru_Guzik: We are super excited to reveal what #AI for drug discovery can do! Paper wirh the wonderful team of biogerontology and InSilicoMeds ! 46 days from AI to candidate molecules. VectorInst UofTCompSci chemuoft UofT #matterlab
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT techreview "RT A_Aspuru_Guzik: We are super excited to reveal what #AI for drug discovery can do! Paper wirh the wonderful team of biogerontology and InSilicoMeds ! 46 days from AI to candidate molecules. VectorInst UofTCompSci chemuoft UofT #matterlab
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @A_Aspuru_Guzik: We are super excited to reveal what #AI for drug discovery can do! Paper wirh the wonderful team of @biogerontology and…
RT @MrJeffKarp: Deep learning enables rapid identification of potent DDR1 kinase inhibitors - a kinase target implicated in fibrosis and ot…
Intriguing paper. We are a very long way from models replacing in vivo testing but for targets with a high degree of knowledge it may be part of the toolkit. Unlike some, this model seems to suggest synth. accessible structures. https://t.co/jlEz38KR6n
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @ElementoLab: First ever demonstration that AI can generate entirely novel, synthesizable, active molecules against specific pharmacolog…
It's happening! AI for Drug Discovery. Continuing to find the accelerator for learning and furthering solutions for patients.
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @MrJeffKarp: Deep learning enables rapid identification of potent DDR1 kinase inhibitors - a kinase target implicated in fibrosis and ot…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @jussileinonen: Insilico Medicine used #AI to design a #drug in 21 days: https://t.co/wrietLQoJ8 “I think that this paper will remove a…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Deep learning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/hMCStOq6Bl
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
Congrats Alex @biogerontology and the @InSilicoMeds team for developing six molecules using GENTRL system, a new #AI system for drug discovery leveraging generative adversarial networks (#GANs) and reinforcement learning (#RL). Nature publication here:
Amazing new work from my colleagues at #Insilico The real breakthrough of generative chemistry in pharma. #NatureBiotechnology #InsilicoVeritas https://t.co/RFSEoCnhi5
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Deep learning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/Heeef3HmgI #deeplearning #AI #nature
RT @blue08613: Deep learning enables rapid identification of potent DDR1 kinase inhibitors | Nature Biotechnology https://t.co/1JP2T9C7C8
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
Insilico Medicine used #AI to design a #drug in 21 days: https://t.co/wrietLQoJ8 “I think that this paper will remove a lot of skepticism in #bigpharma,” @biogerontology says. Published in Nature Biotechnology: https://t.co/PfmtsNwOLZ https://t.co/EMeUr1
RT @MrJeffKarp: Deep learning enables rapid identification of potent DDR1 kinase inhibitors - a kinase target implicated in fibrosis and ot…
RT @bayesgroup: Check out a new paper from @InSilicoMeds coauthored by our members @d_polykovskiy and @Max__Kuznetsov in @NatureBiotech on…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @SiFulle: Nice study employing generative models for compound design https://t.co/NLnQNyD2gb
Congratulations to our collaborator Alex Zhavoronkov @biogerontology CEO @InSilicoMeds for his ground breaking @NatureBiotech publication! This will accelerate AI research in longevity and ageing @ARK_KCL https://t.co/HpE8Yn2Z4a
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Can’t quite get my head around this... mental. The future’s here...
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
The power of #MachineLearning and #AI in #medicine
Original paper is here https://t.co/3FZ1wmLqHd I understand it's interesting to try to utilise deep learning to solve problems, however, it's not the only way.
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
Straight outta Toronto—congrats @VectorInst and @A_Aspuru_Guzik
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @MrJeffKarp: Deep learning enables rapid identification of potent DDR1 kinase inhibitors - a kinase target implicated in fibrosis and ot…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
It's a great honor to be a part of this work. Deep Learning can solve small molecule design! Drug discovery will never be the same. Paper accepted to Nature Biotechnology. Shares of this paper on twitter and facebook are highly welcome! https://t.co/x0YwL
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
We are going from sci-fi to a real change in medicine... Nasze AI znajduje aktywne substancje i daje szansę na nowy lek... https://t.co/V0DbGU0RFp #AI #DrugDiscovery #NewPharma
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @IParkkinen: Wow this is crazy. To nanomolar hits with favorable in vivo PK properties in a couple of weeks😲 https://t.co/kjyuHBYKpN
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @tangming2005: Deep learning enables rapid identification of potent DDR1 kinase inhibitorsDeep learning enables rapid identification of…
RT @tangming2005: Deep learning enables rapid identification of potent DDR1 kinase inhibitorsDeep learning enables rapid identification of…
Наши ребята